IGF-1 LR3 (1mg) protocols center on this long-acting analog of Insulin-like Growth Factor-1 (IGF-1), designed to extend biological activity and enhance anabolic signaling. IGF-1 LR3 is studied for its potential role in supporting muscle growth, recovery, and nutrient partitioning by increasing cellular uptake of amino acids and glucose. This guide outlines a subcutaneous administration format commonly used in research settings for the 1 mg vial.
Concise summary of the research-based regimen.
Suggested research-based approach for the 1 mg vial format.
IGF-1 LR3 (Long R3 IGF-1) is a modified form of insulin-like growth factor-1 with a reduced affinity for IGF-binding proteins, resulting in increased stability and prolonged activity in circulation. This allows for enhanced and sustained activation of IGF-1 receptors.
Once bound to its receptor, IGF-1 LR3 activates signaling pathways such as PI3K/Akt and MAPK, which are associated with increased protein synthesis, cellular growth, and reduced protein breakdown. It also promotes glucose uptake and amino acid transport into muscle cells, supporting anabolic and recovery processes.
Observations based on preclinical and research literature.
Potential Benefits:
Possible Side Effects: